Earnings summaries and quarterly performance for HAEMONETICS.
Executive leadership at HAEMONETICS.
Christopher Simon
Detailed
President and Chief Executive Officer
CEO
FC
Frank Chan
Detailed
Executive Vice President, Chief Operating Officer
JD
James D'Arecca
Detailed
Executive Vice President, Chief Financial Officer
LM
Laurie Miller
Detailed
Senior Vice President, Chief Human Resources Officer
MB
Michelle Basil
Detailed
Executive Vice President, General Counsel
RG
Roy Galvin
Detailed
Executive Vice President, Chief Commercial Officer
Board of directors at HAEMONETICS.
Research analysts who have asked questions during HAEMONETICS earnings calls.
Andrew Cooper
Raymond James
4 questions for HAE
Also covers: AZTA, CDNA, CTKB +12 more
AP
Anthony Petrone
Mizuho Group
4 questions for HAE
Also covers: ADMA, ALC, BSX +22 more
Marie Thibault
BTIG
4 questions for HAE
Also covers: ABT, ARAY, ATRC +15 more
CB
Craig Bijou
Bank of America Securities
3 questions for HAE
Also covers: BLCO, COO, FNA +9 more
Michael Matson
Needham & Company
3 questions for HAE
Also covers: AORT, ATRC, CNMD +22 more
MP
Michael Petusky
Barrington Research
3 questions for HAE
Also covers: ANIK, HSIC, LFCR +8 more
RP
Rohin Patel
JPMorgan Chase & Co.
3 questions for HAE
Also covers: CVRX, INGN, NPCE
DT
David Turkaly
Citizens JMP
2 questions for HAE
Also covers: AXGN, FNA, LNTH +4 more
Joanne Wuensch
Citigroup Inc.
2 questions for HAE
Also covers: ABT, BAX, BDX +18 more
LS
Lawrence Solow
CJS Securities, Inc.
2 questions for HAE
Also covers: BTSG, CDRE, CLH +13 more
Anthony Occhiogrosso
Citigroup Inc.
1 question for HAE
Also covers: IRTC
DR
David Rescott
Baird
1 question for HAE
Also covers: INSP, IRTC, LIVN +7 more
KS
Kristen Stewart
CL King & Associates
1 question for HAE
Also covers: AVNS, CNMD, IART +3 more
LS
Larry Solow
CJS Securities
1 question for HAE
Also covers: ARCB, BTSG, CDRE +14 more
Mike Matson
Needham & Company, LLC
1 question for HAE
Also covers: CNMD, ENOV, ESTA +16 more
Recent press releases and 8-K filings for HAE.
Haemonetics Highlights Strong LRP Performance and Strategic Growth Drivers at J.P. Morgan Conference
HAE
Guidance Update
M&A
Share Buyback
- Haemonetics expects to achieve an 8% total revenue compound annual growth rate and 770 basis points of adjusted operating margin expansion over its four-year Long-Range Plan (FY22-FY26), with adjusted EPS projected to compound at approximately 17%.
- The company has transformed its portfolio, with 85% of FY26 revenue now coming from core high-growth, high-margin businesses, significantly up from 30% in FY22.
- Haemonetics maintains leadership positions in its three core platforms: plasma apheresis (over 50% global market share), viscoelastic testing (TEG, 45% market share), and vascular closure.
- The company recently acquired Vivasure for approximately $60 million to expand into the $300 million large bore closure market, with the PerQseal Elite product currently under FDA review for a planned FY27 launch.
- Capital allocation priorities include organic growth, opportunistic share buybacks ($225 million in the past year), and debt repayment for a $300 million convertible debt maturity in March. Future operating margin expansion is projected at 50-100 basis points annually.
3 days ago
Haemonetics Reports FY25 Performance, Issues FY26 Guidance, and Details Vivasure Acquisition
HAE
Guidance Update
M&A
Earnings
- Haemonetics reported FY25 revenue of $1.36 billion , adjusted EPS of $4.57 , and an adjusted operating margin of 24.0%.
- The company issued FY26 guidance, projecting total reported revenue growth of (1-4%) (or organic, ex-CSL revenue growth of 7-10% ), adjusted EPS between $4.80 and $5.00 , and an adjusted operating margin of 26-27%.
- Strategic growth is driven by its Plasma business, with a ~$1 billion Serviceable Addressable Market (SAM) and ~50% global share , and Interventional Technologies, including the Electrophysiology market with a ~$600 million SAM and ~40% US share.
- Haemonetics acquired Vivasure for up to €185 million , which is expected to unlock a $300 million Total Addressable Market (TAM) and strengthen its vascular closure leadership.
- The business model features 94% recurring revenue and a capital allocation strategy that includes ~$515 million (40%) for M&A out of $1.3 billion total.
3 days ago
Haemonetics Highlights Strong LRP Performance and Strategic Growth Initiatives
HAE
M&A
Share Buyback
Guidance Update
- Haemonetics (HAE) is nearing the completion of its FY22-FY26 Long-Range Plan, expecting an 8% total revenue compound annual growth rate and 770 basis points of adjusted operating margin expansion at the midpoint of its current guidance. This performance is attributed to a portfolio shift, with 85% of FY26 revenue now derived from high-growth, high-margin businesses, up from 30% in FY22.
- The company recently acquired Vivasure for approximately $60 million to expand its vascular closure portfolio into the large bore segment, with the PerQseal Elite product currently under FDA review for a planned FY27 launch.
- Capital allocation priorities include organic growth, M&A (currently paused for IVD improvements), and shareholder returns, with $225 million in share buybacks in the past year and a focus on addressing a $300 million convertible debt maturity by the end of March.
- The plasma franchise, a global leader with over 50% market share and 80% share in the U.S. DMS market, is experiencing significant growth from share gains, price premiums, and normalizing collection volumes, providing a durable source of earnings and free cash flow.
3 days ago
Haemonetics discusses strategic growth and financial performance at J.P. Morgan Healthcare Conference
HAE
M&A
Guidance Update
New Projects/Investments
- Haemonetics reported strong progress on its FY22-FY26 Long-Range Plan, with an expected 8% total revenue compound annual growth rate (13% organic) and 770 basis points of adjusted operating margin expansion at the midpoint of current guidance.
- The company has successfully transformed its portfolio, with 85% of FY26 revenue now derived from core high-growth, high-margin businesses, up from 30% in FY22.
- Haemonetics recently acquired Vivasure for approximately $60 million, expanding its vascular closure offering into the large bore segment, which adds an estimated $300 million addressable market.
- Capital allocation priorities include organic growth, opportunistic share buybacks ($225 million in the past year), and addressing a $300 million convertible debt maturity in March.
- Management expects continued operating margin expansion of 50-100 basis points in future years, driven by operating leverage.
3 days ago
Haemonetics acquires Vivasure, Orchestra BioMed to receive up to $21 million in proceeds
HAE
M&A
New Projects/Investments
- Haemonetics Corporation completed the acquisition of Vivasure Medical Limited on January 9, 2026.
- Orchestra BioMed Holdings, Inc., a strategic holding of Vivasure, expects to receive up to $21 million in cash proceeds from this acquisition.
- Of these proceeds, $11 million is anticipated in 2026, including an approximately $5 million upfront payment and an approximately $6 million first milestone payment.
- The remainder of the proceeds will be received in future revenue earnouts based on the achievement of certain milestones.
4 days ago
Haemonetics Acquires Vivasure Medical
HAE
M&A
New Projects/Investments
- Haemonetics announced the acquisition of Vivasure Medical for €100 million upfront (adjusted to €52 million net) plus up to €85 million in milestone-based contingent payments, financed from cash on hand.
- The deal adds Vivasure’s PerQseal Elite, a fully bioabsorbable intravascular patch with CE mark approval and a U.S. FDA premarket approval application submitted in 2025, to Haemonetics’ interventional portfolio.
- Vivasure Medical reported net liabilities of €120.25 million and cash reserves of €360,000 at the end of 2024.
7 days ago
Haemonetics Acquires Vivasure Medical
HAE
M&A
New Projects/Investments
Product Launch
- Haemonetics Corporation (NYSE: HAE) has acquired Vivasure Medical in a transaction valued up to €185M (~$215M), contingent on the completion of certain milestones.
- Vivasure Medical specializes in fully absorbable technology for percutaneous vessel closure, with its PerQseal® Elite system holding European CE mark approval and having a Premarket Approval (PMA) application submitted to the U.S. FDA.
- This acquisition follows a strategic investment made by Haemonetics in Vivasure Medical in 2022, which included an option to acquire the company.
- The PerQseal® and PerQseal® Elite products are not currently available for sale in the United States.
7 days ago
Haemonetics Acquires Vivasure Medical Limited
HAE
M&A
New Projects/Investments
- Haemonetics Corporation (HAE) announced the acquisition of Vivasure Medical Limited on January 9, 2026, a company specializing in next-generation percutaneous vessel closure technology.
- The acquisition includes an upfront cash payment of €100 million (approximately €52 million net of prior investments and loans) and up to an additional €85 million in contingent consideration.
- Haemonetics financed the transaction using available cash on hand.
- The acquisition is expected to expand Haemonetics' range of closure devices and bolster its presence in the large-bore closure market.
7 days ago
Haemonetics Acquires Vivasure Medical Limited
HAE
M&A
New Projects/Investments
- Haemonetics Corporation announced the acquisition of Vivasure Medical Limited on January 9, 2026.
- The acquisition includes an upfront cash payment of €100 million, or approximately €52 million net of previous investments and loans, and up to an additional €85 million in contingent consideration based on sales growth and milestones.
- Vivasure Medical, based in Galway, Ireland, specializes in next-generation technology for percutaneous vessel closure, including its PerQseal® Elite system which received CE Mark approval in Europe and submitted a Premarket Approval application to the U.S. FDA in 2025.
- This acquisition is expected to expand Haemonetics' range of closure devices, bolstering its presence in the large-bore closure market and its impact in structural heart and endovascular procedures.
7 days ago
Haemonetics Reports Strong Q2 2026 Results, Raises Full-Year Guidance
HAE
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Haemonetics (HAE) reported Q2 2026 revenue of $327 million, reflecting a 5% reported decline but 9% organic growth ex CSL, and adjusted EPS of $1.27, an increase of 13%.
- The company raised its full-year fiscal 2026 adjusted EPS guidance to $4.80-$5.00 per share and its total revenue guidance to a 1%-4% reported decline or 7%-10% organic growth ex CSL.
- Adjusted gross margin reached 60.5% in Q2 2026, an expansion of 380 basis points, and adjusted operating margin expanded 250 basis points to 26.7%.
- Operating cash flow was $111 million in Q2 2026, a 128% increase, and free cash flow was $89 million. Full-year free cash flow guidance was raised to $170-$210 million.
- Plasma revenue grew 19% organically ex CSL in Q2 2026, with its full-year organic growth guidance ex CSL raised to 14%-17%. Hospital revenue grew 4% organically in Q2 2026, with full-year guidance updated to 4%-7% reported and organic growth.
Nov 6, 2025, 1:00 PM
Quarterly earnings call transcripts for HAEMONETICS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more